News

In a study in Japanese patients, omarigliptin provided comparable efficacy and tolerability to Merck’s once-daily DPP-4 inhibitor JANUVIA® (sitagliptin) 50 mg, which is the standard starting dose for

Significant pre-launch activities are well underway as PTC prepares for the commercial launch of Translarna™ (ataluren) in the European Union. In August of this year, Translarna received approval

According to IMS, for the 12 months ending July 2014, the US market for Ketorolac approximated $34 million. As with all products in Sagent’s portfolio, Ketorolac features Sagent’s

A statistically significant and clinically relevant response was seen in a prospectively-identified, substantial sub-group of patients with moderate to severe pain who had relatively intact sensory responses as

The proceeds will be used to finance the Company’s registration program for the natriuretic peptide Ularitide in acute heart failure. "This is a pivotal time for our Company.

Odanacatib, which is firm’s investigational once-weekly cathepsin K inhibitor, has reached the primary endpoints and significantly reduced the risk of osteoporotic hip, spine and non-vertebral fractures compared with

According to Hungarian news agency MTI, the company’s research and development division has produced a drug comprising deuterium-depleted water or DDW, which has potential to trim down the

The AZD3293 is an oral beta secretase cleaving enzyme (BACE) inhibitor, which significantly reduced amyloid beta levels in the cerebro-spinal fluid of Alzheimer’s patients and healthy volunteers in

America will also set up additional field hospitals, deliver more health-care personnel and training health workers in Liberia, Sierra Leone and Guinea, which are among the nations that